Drugs / TO-O-1001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05456724 | Aug 2022 → Dec 2023 | ocular hypertension, open-angle glaucoma | Theratocular Biotek Co. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TO-O-1001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05456724 ↗ |
| Route | Topical | “Route of administration: topical ocular” NCT05456724 ↗ |